PeptidePedia The community reference

Contributions of SelectTrialSam

User contributions·26 logged edits·page 1 of 1

Contributions by SelectTrialSam, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 11,840 edits includes activity predating the current log.

  1. 17:08, 11 Jun 2026 (diff | hist) Number needed to treat 4,718 ±0 de-duplicate a repeated sentence
  2. 03:21, 4 May 2026 (diff | hist) Lyophilisation 28,679 ±0 add short description
  3. 18:49, 2 May 2026 (diff | hist) Missed dose 5,277 ±0 correct the unit conversion — U-100 not U-40
  4. 10:30, 16 Apr 2026 (diff | hist) Talk:SURPASS trial programme 537 +159 /* Active-comparator CVOT */ new section
  5. 09:50, 9 Apr 2026 (diff | hist) Talk:Lixisenatide 400 +130 /* Counter-example framing */ new section
  6. 12:50, 18 Mar 2026 (diff | hist) Talk:Exenatide 611 +184 /* Class-effect caution */ reply
  7. 12:08, 14 Mar 2026 (diff | hist) Shanghai ERP Biotechnology 14,417 ±0 state which lines are held in regional stock
  8. 13:34, 13 Mar 2026 (diff | hist) SURMOUNT trial programme 5,021 ±0 consistent en dashes in ranges
  9. 17:04, 11 Mar 2026 (diff | hist) Retatrutide 7,421 ±0 split §Pharmacology into receptor binding and downstream signalling
  10. 14:45, 2 Feb 2026 (diff | hist) SELECT trial 5,171 ±0 m add category for the trial programme
  11. 09:40, 19 Jan 2026 (diff | hist) Talk:SELECT trial 400 +192 /* Early curve separation */ new section
  12. 05:19, 18 Jan 2026 (diff | hist) Zhuhai Kerui Biotechnology 13,405 +487 clarify that no manufacturing or marketing authorisation is claimed or established
  13. 15:02, 17 Jan 2026 (diff | hist) Talk:GLP-1 receptor agonist 748 +138 /* Should class-level cardiovascular benefit be claimed? */ reply
  14. 11:09, 26 Nov 2025 (diff | hist) USP General Chapter 85 5,180 ±0 add category for method validation
  15. 12:13, 6 Nov 2025 (diff | hist) Subcutaneous injection 5,293 ±0 add the dead-space volume to the worked example
  16. 14:41, 29 Oct 2025 (diff | hist) Number needed to treat 4,718 ±0 correct the follow-up duration — the source gives weeks, we had months
  17. 08:09, 18 Aug 2025 (diff | hist) High-performance liquid chromatography 6,815 ±0 m rm the claim that the method is stability-indicating without a forced-degradation study
  18. 00:02, 7 Jul 2025 (diff | hist) Glucagon 7,074 +455 m add category for the drug class
  19. 04:09, 3 Jun 2025 (diff | hist) Good manufacturing practice 4,901 ±0 m state that research-use-only labelling is a commercial category, not an approval
  20. 05:01, 23 May 2025 (diff | hist) SELECT trial 4,851 +645 name the funder in the sentence, per PP:MOS
  21. 01:17, 5 May 2025 (diff | hist) Underfilling 3,432 ±0 split §What a report shows from §What it does not
  22. 09:35, 21 Jan 2025 (diff | hist) Subcutaneous injection 4,039 +194 add the note that a smaller diluent volume raises concentration, not dose
  23. 14:31, 4 Jan 2025 (diff | hist) SELECT trial 4,177 +630 m add the comparator arm — an event rate alone says nothing
  24. 15:02, 24 Nov 2024 (diff | hist) Research use only 4,722 +996 add the jurisdiction to the legal statement
  25. 19:54, 27 Oct 2024 (diff | hist) Fmoc chemistry 3,348 +665 m state the difference between a validated shipper and an insulated box
  26. 20:00, 28 Sep 2024 (diff | hist) Tirzepatide 4,706 +840 add category for the drug class